<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoecon Open</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoecon Open</journal-id><journal-title-group><journal-title>PharmacoEconomics Open</journal-title></journal-title-group><issn pub-type="ppub">2509-4262</issn><issn pub-type="epub">2509-4254</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35997900</article-id><article-id pub-id-type="pmc">PMC9397161</article-id><article-id pub-id-type="publisher-id">359</article-id><article-id pub-id-type="doi">10.1007/s41669-022-00359-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Darrudi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Daroudi</surname><given-names>Rajabali</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yunesian</surname><given-names>Masud</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Akbari Sari</surname><given-names>Ali</given-names></name><address><email>akbarisari@tums.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Department of Health Management and Economics, School of Public Health, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Poursina Ave., 1417613191 Tehran, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Department of Environmental Health Engineering, School of Public Health, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2022</year></pub-date><volume>6</volume><issue>5</issue><fpage>669</fpage><lpage>679</lpage><history><date date-type="accepted"><day>18</day><month>7</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and objective</title><p id="Par1">The coronavirus disease 2019 (COVID-19) pandemic is a major international threat and vaccination is the most robust strategy to terminate this crisis. It is helpful for policymakers to be aware of community preferences about vaccines. The present study aims to investigate the public&#x02019;s preferences and willingness to pay for the COVID-19 vaccine in Iran.</p></sec><sec><title>Methods</title><p id="Par2">This research is a cross-sectional study performed using a discrete choice experiment for a sample of the public population of several provinces of Iran in 2021. The samples were divided into two groups: one group expressed their preferences regarding the vaccine&#x02019;s attributes, and another group expressed their preferences regarding prioritizing individuals to get the vaccine. The discrete choice experiment design included five attributes including effectiveness, risk of severe complications, price, location of vaccine production, and duration of protection related to preferences for vaccine selection and six attributes including age, underlying diseases, employment in the healthcare sector, the rate of virus spread, the necessary job, and cost to the community related to preferences for prioritizing individuals to get the vaccine. A total of 715 individuals completed the questionnaire. The conditional logit regression model was used to analyze the discrete choice experiment data. Willingness to pay for each attribute was also calculated.</p></sec><sec><title>Results</title><p id="Par3">The willingness to pay for the COVID-19 vaccine with 90% (70%) efficacy, the risk of severe complications for 1 (5) person per one million people, imported (domestic) vaccine, and 24-month (12-month) duration of protection attributes was about US$71 (US$37). The preference for vaccination for respondents was enhanced by increasing the efficacy and the duration of vaccine protection and decreasing complications and costs. The likelihood of prioritizing individuals to get a vaccination was increased for a person with an underlying disease, employment in the healthcare sector, the necessary job for the community, the high potential for virus spread in the community, and the high cost of death to the community. The age variable was not statistically significant for prioritizing individuals to get the vaccine.</p></sec><sec><title>Conclusions</title><p id="Par4">In the setting of the COVID-19 vaccination program, the public&#x02019;s preferences identified in this study should be considered. The obtained results provide useful information for policymakers to identify individual and social values for an appropriate vaccination strategy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s41669-022-00359-x.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003968</institution-id><institution>Iran National Science Foundation (INSF)</institution></institution-wrap></funding-source><award-id>4000775</award-id><principal-award-recipient><name><surname>Akbari Sari</surname><given-names>Ali</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d32e258"><title>Key Points for Decision Makers</title><p id="Par05">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">The willingness to pay for the coronavirus disease 2019 vaccine was about US$71 for a vaccine with 90% effectiveness, a risk of severe complications for 1 person per 1 million people, imported vaccine, and 24-month duration of protection attributes.</td></tr><tr><td align="left">Risk of severe side effects and efficacy were the strongest attributes of the public&#x02019;s preferences for vaccine selection.</td></tr><tr><td align="left">Potential capacity to spread the virus in the community and employment in the healthcare sector were the strongest attributes of the public&#x02019;s preferences for prioritizing individuals to get the vaccine.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1"><title>Introduction</title><p id="Par9">The current global coronavirus disease 2019 (COVID-19) pandemic is a major international threat. Coronavirus disease is caused by severe acute respiratory syndrome coronavirus 2 [<xref ref-type="bibr" rid="CR1">1</xref>]. By 20 November, 2021, more than 257 million confirmed cases of COVID-19 were reported globally, with more than 5 million deaths [<xref ref-type="bibr" rid="CR2">2</xref>]. In Iran, more than 6 million confirmed cases of COVID-19 and more than 128,000 deaths have been reported to date [<xref ref-type="bibr" rid="CR3">3</xref>]. Although some drugs have been used to treat patients with COVID-19 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], no specific treatment has been approved by international organizations. Therefore, vaccination is one of the most promising strategies in this crisis.</p><p id="Par10">Even with the availability of a safe and effective COVID-19 vaccine, it is not clear whether people will accept or buy the vaccine. Therefore, it is essential to evaluate the vaccine&#x02019;s acceptance rate and the willingness to pay (WTP) for the vaccine. The evaluation of WTP for the vaccine, defined as the maximum amount of money that people are willing to pay for a vaccine, determines the potential market and obtains information that can be used to formulate the best payment strategy for a new vaccine. The WTP is influenced by many factors, including sociological and demographic characteristics and individuals&#x02019; previous attitudes and beliefs. These factors in different societies do not necessarily have a fixed relationship to the WTP. Therefore, identifying the determinants associated with the WTP for the COVID-19 vaccine is essential for the government and other organizations to design an excellent intervention to be used in key populations [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Studies have evaluated the acceptance and the WTP for the COVID-19 vaccine globally but in Iran such evidence is limited [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par11">Another issue after vaccine acceptance by individuals is that when the COVID-19 vaccine becomes available there will not be enough supply to vaccinate the entire population. That is why policymakers are developing vaccine prioritization strategies at national and international levels [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par12">Rationing can fill the gap between service and available sources. The consequences of rationing include prioritizing services, effective resource allocation, and the effective management of resource distribution [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. According to a study conducted in 2018, there are 12 types of strategies for rationing in health, including explicit and implicit rationing, rationing based on price or monetary rationing, and rationing based on age [<xref ref-type="bibr" rid="CR15">15</xref>]. However, these strategies must enjoy adequate public support. Therefore, it is also necessary to determine the public&#x02019;s preferences about the vaccine.</p><p id="Par13">The discrete choice experiment (DCE) is the most ordinal method that calculates the WTP and determines the public&#x02019;s preference in the healthcare sector [<xref ref-type="bibr" rid="CR16">16</xref>]. For the first time, this study is using the DCE method to estimate the WTP and the public&#x02019;s preferences for a COVID-19 vaccine in Iran.</p></sec><sec id="Sec2"><title>Method</title><p id="Par14">In this cross-sectional study, the DCE method was used to calculate the WTP and determine the public&#x02019;s preferences for the COVID-19 vaccine. The public&#x02019;s preferences have been measured regarding both the vaccine type and prioritizing individuals to get the vaccine.</p><sec id="Sec3"><title>Identification of Attributes and Levels</title><p id="Par15">First, a list of attributes was extracted by reviewing studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] and expert opinions. The first list of attributes and levels included 19 attributes at different levels for the vaccine and 11 attributes at different levels for individuals (see Table 1 in the Electronic Supplementary Material [ESM]). Then, the final attributes were selected by a panel consisting of experts from the fields of health economics, virology, health policymaking, and healthcare management (seven people), by ranking attributes, of which five attributes were related to the vaccine and six attributes were related to individuals.</p><p id="Par16">The five attributes related to preferences for vaccine selection included effectiveness, risk of severe complications, price, location of vaccine production, and duration of protection. The six attributes related to preferences for prioritizing individuals to get the vaccine were age, underlying diseases, employment in the healthcare sector, the rate of virus spread, the necessary job for the community, and cost to the community. The levels of relevant attributes were also chosen using articles and the opinions of experts so that they could cover the essential dimensions of the COVID-19 vaccine and individuals in the community (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Attributes and levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Section</th><th align="left">Attributes</th><th align="left">Levels</th></tr></thead><tbody><tr><td align="left" rowspan="5">Public&#x02019;s preferences for vaccine selection</td><td align="left">Effectiveness (%)</td><td align="left"><p>50%</p><p>70%</p><p>90%</p></td></tr><tr><td align="left">Risk of severe side effects (anaphylactic shock or death)</td><td align="left"><p>1 person per one million people</p><p>5 people per one million people</p><p>10 people per one million people</p></td></tr><tr><td align="left">Price (Rials and US$)</td><td align="left"><p>Free</p><p>500 thousand Rials ($2)</p><p>1 million Rials ($4)</p><p>2 million Rials ($8)</p><p>5 million Rials ($20)</p></td></tr><tr><td align="left">Location of vaccine production</td><td align="left"><p>Imported</p><p>Domestic production</p></td></tr><tr><td align="left">Protection period (months)</td><td align="left"><p>6 months</p><p>12 months</p><p>24 months</p></td></tr><tr><td align="left" rowspan="6">Public&#x02019;s preferences for prioritizing individuals to get the vaccine</td><td align="left">Age</td><td align="left"><p>Less than 60 years</p><p>More than 60 years</p></td></tr><tr><td align="left">Underlying diseases (such as high blood pressure and diabetes mellitus)</td><td align="left"><p>Have</p><p>Not have</p></td></tr><tr><td align="left">Employment in the health sector (direct contact with coronavirus patients)</td><td align="left"><p>Yes</p><p>No</p></td></tr><tr><td align="left">Potential capacity to spread the virus in the community or the extent of the virus</td><td align="left"><p>Low (1&#x02013;2 people)</p><p>Medium (3&#x02013;5 people)</p><p>Many (5&#x02013;10 people)</p></td></tr><tr><td align="left">The necessary job for society</td><td align="left"><p>It is necessary for society</p><p>It is not necessary for society</p></td></tr><tr><td align="left">Cost to the community or the amount of damage to the community in the event of death and disability</td><td align="left"><p>Low</p><p>Medium</p><p>High</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Selection of Experimental Design</title><p id="Par17">In the present research, for the public&#x02019;s preferences regarding the vaccine selection, one attribute at five levels, one attribute at two levels, and three attributes at five levels, and for the public&#x02019;s preferences regarding prioritizing individuals to get the vaccine, two attributes at three levels and four attributes at two levels were included. Using the full factorial design, the total combinations led to 270<xref ref-type="fn" rid="Fn1">1</xref> scenarios and 36,315<xref ref-type="fn" rid="Fn2">2</xref> possible pairwise choices to calculate the WTP and the public&#x02019;s preferences for the COVID-19 vaccine and 144<xref ref-type="fn" rid="Fn3">3</xref> scenarios and 10,296<xref ref-type="fn" rid="Fn4">4</xref> possible pairwise choices to evaluate the public&#x02019;s preferences for prioritizing individuals in the community to get the vaccine. To resolve the difficulty of responding to this number of choice sets using the fractional factorial and D-efficiency in Stata software, 36 choice sets were developed to examine the public&#x02019;s preferences regarding vaccine selection, and 30 choice sets were provided to examine the public&#x02019;s preferences regarding prioritizing individuals to get the vaccine. The choice sets of public&#x02019;s preferences regarding the vaccine selection were divided into four blocks and each block consisted of nine choice sets. The choice sets of public&#x02019;s preferences regarding prioritizing individuals to get the vaccine were divided into three blocks and each block consisted of ten choice sets. In this study, there were two series of choice sets: one series related to the vaccine and another related to prioritizing individuals. An example of these choice sets is given in Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. (The figures are English translations.)<fig id="Fig1"><label>Fig. 1</label><caption><p>Example of a discrete choice experiment choice set for vaccine selection</p></caption><graphic xlink:href="41669_2022_359_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Example of a discrete choice experiment choice set for prioritizing people. <italic>COVID-19</italic> coronavirus disease 2019</p></caption><graphic xlink:href="41669_2022_359_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Questionnaire Development and Data Collection</title><p id="Par22">Given that there were four blocks of nine choice sets for the vaccine and three blocks of ten choice sets for individuals, seven editions of the questionnaire were prepared. All questionnaires were similar and differed only in choice sets, and each individual was given only one questionnaire. The questionnaire included DCE questions and demographic questions of individuals (see the English translation of questionnaires in the ESM). Considering that the study questionnaire was the result of the opinions of experts and specialists, the content validity was confirmed by them; nevertheless, the validity of the final version of the questionnaire was approved by six experts in this field. However, as statistical methods have been used to design selection sets, this tool generally had appropriate validity and reliability. In a pilot study (30 people), the questionnaire reliability was also examined. In the assessment of the respondent&#x02019;s perception of the choice sets, in other words, the questionnaire&#x02019;s internal validity, the dominant choice set was entered into the vaccine choice sets as a test of rationality in the questionnaire, in which one scenario was logically and superior to the opposite scenario. Therefore, all individuals who carefully responded to the questionnaire were expected to choose the dominant option; thus, those who did not respond correctly to the dominant option were excluded from the study.</p><p id="Par23">Data were collected from 21 March to 6 July, 2021, among the general population over 18 years of age in the Tehran province and several other provinces (Khorasan Razavi, Isfahan, Alborz) [see Table 2 in the ESM]. The convenience sampling method was used to select the sampling units. Data collection was performed both online (415 participants) and in person (300 participants) to increase generalizability by the research team members. In the online stage of collecting the questionnaires, an online questionnaire was designed using the EPOLL website, and the questionnaire link was sent to individuals through communication channels such as text messages and communication groups. In the in-person collection stage, the designed online questionnaire was completed according to individuals&#x02019; answers in public places (hospitals, government centers, public spaces) by the research team members using tablets. Individuals who answered the dominant question incorrectly, completed the questionnaire incompletely, or refused to continue completing the questionnaire for any reason were excluded from the final analysis.</p></sec><sec id="Sec6"><title>Statistical Analysis</title><p id="Par24">The conditional logit is one of the common estimation models used for statistical analysis [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. The selection set was estimated by a conditional logit regression model using Stata software. Only the main effect was estimated in this study. As the proposed vaccines and individuals are binary (<italic>V</italic> = 1, if the vaccine or individual is selected; <italic>V</italic> = 0, if the vaccine or individual is not selected), the estimated models for the vaccine and individuals (two models) are as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{{\text{vaccine selection}}} = \, \beta {\text{1 effectiveness}}_{{{7}0\% }} + \, \beta {\text{2 effectiveness}}_{{{9}0\% }} + \, \beta {\text{3 serious side effects}}_{{{5}:{1}000000}} + \, \beta {\text{4 serious side effects}}_{{{1}:{1}000000}} + \, \beta {\text{5 cost}}_{{{8}\$ }} + \, \beta {\text{6 cost}}_{{{4}\$ }} + \, \beta {\text{7 cost}}_{{{2}\$ }} + \, \beta {\text{8 cost}}_{{{\text{free}}}} + \, \beta {\text{9 product}}_{{{\text{import}}}} + \, \beta {1}0{\text{ duration}}_{{{12}}} + \, \beta {\text{11 duration}}_{{{24}}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>vaccine selection</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>1 effectiveness</mml:mtext></mml:mrow><mml:mrow><mml:mn>70</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>2 effectiveness</mml:mtext></mml:mrow><mml:mrow><mml:mn>90</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>3 serious side effects</mml:mtext></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mo>:</mml:mo><mml:mn>1000000</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>4 serious side effects</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mn>1000000</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>5 cost</mml:mtext></mml:mrow><mml:mrow><mml:mn>8</mml:mn><mml:mi mathvariant="normal">$</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>6 cost</mml:mtext></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mi mathvariant="normal">$</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>7 cost</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi mathvariant="normal">$</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>8 cost</mml:mtext></mml:mrow><mml:mtext>free</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>9 product</mml:mtext></mml:mrow><mml:mtext>import</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:mn>10</mml:mn><mml:msub><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>duration</mml:mtext></mml:mrow><mml:mn>12</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>11 duration</mml:mtext></mml:mrow><mml:mn>24</mml:mn></mml:msub></mml:mrow></mml:math><graphic xlink:href="41669_2022_359_Article_Equa.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{{\text{prioritizing individuals to get the vaccine}}} = \, \beta {\text{1 Age}}_{{{\text{More than 6}}0{\text{ years}}}} + \, \beta {\text{2 underlying disease}}_{{{\text{have}}}} + \, \beta {\text{3 employment in the health sector}}_{{{\text{Yes}}}} + \, \beta {\text{4 virus spread rate}}_{{{\text{medium}}}} + \, \beta {\text{5 virus spread rate}}_{{{\text{Much}}}} + \, \beta {\text{6 job necessary }} + \, \beta {\text{7 costs for the community}}_{{{\text{medium}}}} + \, \beta {\text{8 costs for the community}}_{{{\text{Much}}}}$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mtext>prioritizing individuals to get the vaccine</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>1 Age</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mtext>More than 6</mml:mtext></mml:mrow><mml:mn>0</mml:mn><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>years</mml:mtext></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>2 underlying disease</mml:mtext></mml:mrow><mml:mtext>have</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>3 employment in the health sector</mml:mtext></mml:mrow><mml:mtext>Yes</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>4 virus spread rate</mml:mtext></mml:mrow><mml:mtext>medium</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>5 virus spread rate</mml:mtext></mml:mrow><mml:mtext>Much</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mtext>6 job necessary</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>7 costs for the community</mml:mtext></mml:mrow><mml:mtext>medium</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mspace width="0.166667em"/><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mtext>8 costs for the community</mml:mtext></mml:mrow><mml:mtext>Much</mml:mtext></mml:msub></mml:mrow></mml:math><graphic xlink:href="41669_2022_359_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par25">The willingness for final payment for an attribute level equals the final replacement rate between the level and attribute cost. Therefore, if the price attribute coefficient was <italic>b</italic> and the coefficient of levels of one of the studied attributes was <italic>b</italic><sub>1</sub>, the WTP would be obtained through the following relationship:<disp-formula id="Equc"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{WTP}} = - {b}_{1}/b.$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:mtext>WTP</mml:mtext><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>b</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xlink:href="41669_2022_359_Article_Equc.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par26">The exchange rate for converting IR.Rials to US$ was IR.Rials 257,000 = US$1 at the time of the study. All analyses were performed using STATA software version 13.1.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Sample Characteristics</title><p id="Par27">In this study, a total of 715 people completed the questionnaire (including the pilot study and the main study). Four hundred and ten people expressed their preferences regarding the vaccine attributes, and 305 people expressed their preferences regarding prioritizing individuals to get the vaccine. In the descriptive findings section, all of these questionnaires were included in the study, but in the analytical section, 22 people were removed because of a short response time less than the minimum time required to respond (6 minutes), and eight people were excluded from the analyses because of incorrect responses to the dominant option, and 685 people finally remained.</p><p id="Par28">The subjects&#x02019; demographic characteristics are presented in Table <xref rid="Tab2" ref-type="table">2</xref>. In this study, 59% were female and about 71% were aged under 40 years (mean age = 34.64 years). About 73% had a bachelor&#x02019;s degree or higher, and over 47% were employed. About 62% of the subjects were married, and 69% were not heads of households. The average number of household members was 3.65, and 54% had households of at least four people. About 90% of the subjects were covered by one of the health insurers. Moreover, 45% of the participants had supplementary insurance. The monthly income and expenses of most participants were US$156&#x02013;US$233 (25%) and US$156&#x02013;US$233 (29%), respectively, and 13% of participants had a history of illness, physical problems, or a disability including mental health issues, obesity, and blood pressure (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Characteristics of all respondents</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Frequency</th><th align="left">Percentage</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Female</td><td align="left">420</td><td char="." align="char">58.74</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">295</td><td char="." align="char">41.26</td></tr><tr><td align="left">Age (years)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;18&#x02013;29</td><td align="left">252</td><td char="." align="char">35.24</td></tr><tr><td align="left">&#x000a0;30&#x02013;39</td><td align="left">254</td><td char="." align="char">35.52</td></tr><tr><td align="left">&#x000a0;40&#x02013;49</td><td align="left">127</td><td char="." align="char">17.76</td></tr><tr><td align="left">&#x000a0;50&#x02013;59</td><td align="left">60</td><td char="." align="char">8.39</td></tr><tr><td align="left">&#x000a0;60&#x02013;69</td><td align="left">20</td><td char="." align="char">2.80</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x000a0;69</td><td align="left">2</td><td char="." align="char">0.28</td></tr><tr><td align="left">Educational status</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Associate degree and lower</td><td align="left">190</td><td char="." align="char">26.57</td></tr><tr><td align="left">&#x000a0;Bachelor</td><td align="left">206</td><td char="." align="char">28.81</td></tr><tr><td align="left">&#x000a0;Masters</td><td align="left">180</td><td char="." align="char">25.18</td></tr><tr><td align="left">&#x000a0;PhD and higher</td><td align="left">139</td><td char="." align="char">19.44</td></tr><tr><td align="left">Employment status</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Employed</td><td align="left">339</td><td char="." align="char">47.40</td></tr><tr><td align="left">&#x000a0;Unemployed</td><td align="left">242</td><td char="." align="char">33.84</td></tr><tr><td align="left">&#x000a0;Housewife</td><td align="left">104</td><td char="." align="char">14.55</td></tr><tr><td align="left">&#x000a0;Retired</td><td align="left">30</td><td char="." align="char">4.20</td></tr><tr><td align="left">Marital status</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Single</td><td align="left">251</td><td char="." align="char">35.10</td></tr><tr><td align="left">&#x000a0;Married</td><td align="left">443</td><td char="." align="char">61.96</td></tr><tr><td align="left">&#x000a0;Widowed/divorced</td><td align="left">21</td><td char="." align="char">2.94</td></tr><tr><td align="left">Heads of households</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">224</td><td char="." align="char">31.33</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">491</td><td char="." align="char">68.67</td></tr><tr><td align="left">Total number of household members</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x02264;&#x000a0;3</td><td align="left">330</td><td char="." align="char">46.15</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x000a0;4</td><td align="left">385</td><td char="." align="char">53.85</td></tr><tr><td align="left">Health insurance</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Have</td><td align="left">643</td><td char="." align="char">89.93</td></tr><tr><td align="left">&#x000a0;Not have</td><td align="left">72</td><td char="." align="char">10.07</td></tr><tr><td align="left">Supplementary insurance</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Have</td><td align="left">322</td><td char="." align="char">45.03</td></tr><tr><td align="left">&#x000a0;Not have</td><td align="left">393</td><td char="." align="char">54.97</td></tr><tr><td align="left">Monthly household income ($)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x0003c;&#x000a0;78</td><td align="left">64</td><td char="." align="char">8.95</td></tr><tr><td align="left">&#x000a0;78&#x02013;156</td><td align="left">160</td><td char="." align="char">22.38</td></tr><tr><td align="left">&#x000a0;156&#x02013;233</td><td align="left">179</td><td char="." align="char">25.03</td></tr><tr><td align="left">&#x000a0;233&#x02013;311</td><td align="left">137</td><td char="." align="char">19.16</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x000a0;311</td><td align="left">175</td><td char="." align="char">24.48</td></tr><tr><td align="left">Monthly household expenditure ($)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x0003c;&#x000a0;78</td><td align="left">47</td><td char="." align="char">6.57</td></tr><tr><td align="left">&#x000a0;78&#x02013;156</td><td align="left">186</td><td char="." align="char">26.01</td></tr><tr><td align="left">&#x000a0;156&#x02013;233</td><td align="left">208</td><td char="." align="char">29.09</td></tr><tr><td align="left">&#x000a0;233&#x02013;311</td><td align="left">139</td><td char="." align="char">19.44</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x000a0;311</td><td align="left">135</td><td char="." align="char">18.88</td></tr><tr><td align="left">Illness, physical problem, or disability</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">94</td><td char="." align="char">13.15</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">621</td><td char="." align="char">86.85</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Estimating the Public&#x02019;s Preferences for the COVID-19 Vaccine Using the Conditional Logit Model</title><p id="Par29">Table <xref rid="Tab3" ref-type="table">3</xref> shows that the coefficients of all attributes were statistically significant. The results showed that the highest coefficients were related to the complications of 1 person per one million people (<italic>b</italic> = 1.253, <italic>p</italic> &#x0003c; 0.000) and 90% effectiveness attributes (<italic>b</italic> = 0.902, <italic>p</italic> &#x0003c; 0.000). Respondents&#x02019; preferences for the COVID-19 vaccine increased with greater efficacy and a longer duration of protection and decreased with an increased price and severe complications. In addition, the location of vaccine production also affected the respondents&#x02019; preference, and the imported vaccines had a higher chance of acceptance than the domestically produced vaccines. The odds ratio of efficacy attribute was 2.46, indicating that the odds of accepting a vaccine with a higher efficacy (90%) is 2.46 higher than a vaccine with a lower efficacy (50%) (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Conditional logit model of the public&#x02019;s preferences for the coronavirus disease 2019 vaccine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Attribute/level</th><th align="left" rowspan="2">Coefficient</th><th align="left" colspan="2">Odds ratio</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left">Odds ratio</th><th align="left">95%<break/>Confidence interval</th></tr></thead><tbody><tr><td align="left">Effectiveness (%)</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;50</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;70</td><td align="left">0.427</td><td char="." align="char">1.533</td><td char="&#x02013;" align="char">1.377&#x02013;1.707</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;90</td><td align="left">0.902</td><td char="." align="char">2.465</td><td char="&#x02013;" align="char">2.199&#x02013;2.763</td><td char="." align="char">0.000</td></tr><tr><td align="left">Risk of severe side effects</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;10 people per one million people</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;5 people per one million people</td><td align="left">0.761</td><td char="." align="char">2.140</td><td char="&#x02013;" align="char">1.914&#x02013;2.393</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;1 person per one million people</td><td align="left">1.253</td><td char="." align="char">3.502</td><td char="&#x02013;" align="char">3.127&#x02013;3.923</td><td char="." align="char">0.000</td></tr><tr><td align="left">Price ($)</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;20</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;8</td><td align="left">0.499</td><td char="." align="char">1.647</td><td char="&#x02013;" align="char">1.404&#x02013;1.932</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;4</td><td align="left">0.560</td><td char="." align="char">1.751</td><td char="&#x02013;" align="char">1.494&#x02013;2.053</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">0.585</td><td char="." align="char">1.795</td><td char="&#x02013;" align="char">1.525&#x02013;2.113</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;Free</td><td align="left">0.757</td><td char="." align="char">2.133</td><td char="&#x02013;" align="char">1.822&#x02013;2.497</td><td char="." align="char">0.000</td></tr><tr><td align="left">Location of vaccine production</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Domestic production</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Imported</td><td align="left">0.078</td><td char="." align="char">1.081</td><td char="&#x02013;" align="char">1.000&#x02013;1.169</td><td char="." align="char">0.049</td></tr><tr><td align="left">Protection period (months)</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;6</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;12</td><td align="left">0.179</td><td char="." align="char">1.196</td><td char="&#x02013;" align="char">1.070&#x02013;1.336</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#x000a0;24</td><td align="left">0.389</td><td char="." align="char">1.475</td><td char="&#x02013;" align="char">1.324&#x02013;1.644</td><td char="." align="char">0.000</td></tr><tr><td align="left"><italic>N</italic></td><td align="left">386</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Number of obs</td><td align="left">6924</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Prob &#x0003e; chi-square</td><td align="left">0.0000</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Log-likelihood</td><td align="left">&#x02212;&#x000a0;1929.542</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Pseudo R2</td><td align="left">0.1959</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><italic>obs</italic> observations, <italic>Prob</italic> probability</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Estimating the Public&#x02019;s Preferences for Prioritizing Individuals to Get the COVID-19 Vaccine Using the Conditional Logit Model</title><p id="Par30">Table <xref rid="Tab4" ref-type="table">4</xref> shows that the coefficients of all attributes except for age were statistically significant. The results showed that the highest coefficients were related to the attributes of a high rate of virus spread (<italic>b</italic> = 0.947, <italic>p</italic> &#x0003c; 0.001) and employment in the healthcare sector (<italic>b</italic> = 0.574, <italic>p</italic> &#x0003c; 0.001). Respondents&#x02019; preferences for choosing a person to get the vaccine increased with the underlying disease, employment in the healthcare sector, increasing potential for virus spread in the community, necessary job for the community, and the high cost of death to the community. The odds ratio of having an underlying disease was 1.47, indicating that an individual with an underlying disease was more likely to be chosen to get the vaccine than a person without an underlying disease (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Conditional logit model of the public&#x02019;s preferences for prioritizing receiving the coronavirus disease 2019 vaccine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Attribute/level</th><th align="left" rowspan="2">Coefficient</th><th align="left" colspan="2">Odds ratio</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left">Odds ratio</th><th align="left">95%<break/>Confidence interval</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Less than 60</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;More than 60</td><td align="left">&#x02212;&#x000a0;0.058</td><td char="." align="char">0.943</td><td char="&#x02013;" align="char">0.867&#x02013;1.025</td><td char="." align="char">0.171</td></tr><tr><td align="left">Underlying disease</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Not have</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Have</td><td align="left">0.388</td><td char="." align="char">1.474</td><td char="&#x02013;" align="char">1.355&#x02013;1.602</td><td char="." align="char">0.000</td></tr><tr><td align="left">Employment in the health sector</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">0.574</td><td char="." align="char">1.777</td><td char="&#x02013;" align="char">1.635&#x02013;1.931</td><td char="." align="char">0.000</td></tr><tr><td align="left">Potential capacity to spread the virus (virus spread)</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Low (1&#x02013;2 people)</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Medium (3&#x02013;5 people)</td><td align="left">0.450</td><td char="." align="char">1.568</td><td char="&#x02013;" align="char">1.397&#x02013;1.761</td><td char="." align="char">0.000</td></tr><tr><td align="left">&#x000a0;Many (5&#x02013;10 people)</td><td align="left">0.947</td><td char="." align="char">2.578</td><td char="&#x02013;" align="char">2.280&#x02013;2.915</td><td char="." align="char">0.000</td></tr><tr><td align="left">The necessary job for society</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;It is not necessary for society</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;It is necessary for society</td><td align="left">0.396</td><td char="." align="char">1.485</td><td char="&#x02013;" align="char">1.368&#x02013;1.613</td><td char="." align="char">0.000</td></tr><tr><td align="left">Cost to the community</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Low</td><td align="left">Reference</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Medium</td><td align="left">0.166</td><td char="." align="char">1.180</td><td char="&#x02013;" align="char">1.053&#x02013;1.324</td><td char="." align="char">0.004</td></tr><tr><td align="left">&#x000a0;High</td><td align="left">0.556</td><td char="." align="char">1.745</td><td char="&#x02013;" align="char">1.555&#x02013;1.958</td><td char="." align="char">0.000</td></tr><tr><td align="left"><italic>N</italic></td><td align="left">299</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Number of obs</td><td align="left">5962</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Prob &#x0003e; chi-square</td><td align="left">0.0000</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Log-likelihood</td><td align="left">&#x02212;&#x000a0;1723.2727</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Pseudo R2</td><td align="left">0.1660</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><italic>obs</italic> observations,&#x000a0;<italic>Prob</italic> probability</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Estimating WTP for the Vaccine</title><p id="Par31">Estimating the WTP shows that respondents are willing to pay more for higher efficacy and a longer duration of protection than other attributes. An individual was shown to be willing to pay US$24.50 on average for a vaccine with 90% efficacy, US$34.24 for the risk of severe complications of 1 person per million people, US$1.96 for the imported vaccines, and US$10.48 for the 24-month duration of protection. For example, the WTP for a hypothetical vaccine with 70% efficacy, the risk of severe complications of 5 people per 1 million people, an imported vaccine, and the 12-month duration of protection is equal to US$39.16 (Table <xref rid="Tab5" ref-type="table">5</xref> and Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>WTP of individuals for different levels of attributes of the coronavirus disease 2019 vaccine based on the conditional logit model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Attribute/level</th><th align="left" rowspan="2">Coefficient</th><th align="left" colspan="4">WTP</th></tr><tr><th align="left">IR.Rials</th><th align="left">US$</th><th align="left" colspan="2">95% Confidence interval</th></tr></thead><tbody><tr><td align="left">Effectiveness (%)</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;70</td><td char="." align="char">0.430</td><td char="," align="char">3,004,635</td><td char="." align="char">11.69</td><td char="." align="char">7.37</td><td char="." align="char">18.28</td></tr><tr><td align="left">&#x000a0;90</td><td char="." align="char">0.900</td><td char="," align="char">6,297,037</td><td char="." align="char">24.50</td><td char="." align="char">17.90</td><td char="." align="char">34.62</td></tr><tr><td align="left">Risk of severe side effects</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;5 people per one million people</td><td char="." align="char">0.762</td><td char="," align="char">5,327,291</td><td char="." align="char">20.73</td><td char="." align="char">14.80</td><td char="." align="char">29.80</td></tr><tr><td align="left">&#x000a0;1 person per one million people</td><td char="." align="char">1.258</td><td char="," align="char">8,800,021</td><td char="." align="char">34.24</td><td char="." align="char">26.05</td><td char="." align="char">46.82</td></tr><tr><td align="left">Location of vaccine production</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Imported</td><td char="." align="char">0.072</td><td char="," align="char">503,357</td><td char="." align="char">1.96</td><td char="." align="char">&#x02212; 0.13</td><td char="." align="char">5.10</td></tr><tr><td align="left">Protection period (months)</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;12</td><td char="." align="char">0.176</td><td char="," align="char">1,229,041</td><td char="." align="char">4.78</td><td char="." align="char">1.52</td><td char="." align="char">9.72</td></tr><tr><td align="left">&#x000a0;24</td><td char="." align="char">0.385</td><td char="," align="char">2,692,840</td><td char="." align="char">10.48</td><td char="." align="char">6.31</td><td char="." align="char">16.82</td></tr><tr><td align="left">Price</td><td char="." align="char">&#x02212;&#x000a0;0.000001</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><italic>WTP</italic> willingness to pay</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Willingness to pay of individuals for different levels of attributes of the coronavirus 2019 vaccine based on the conditional logit model</p></caption><graphic xlink:href="41669_2022_359_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par32">COVID-19 is, at present, a global dilemma. Prevention by vaccination leads to reduced human losses and casualties. In the present study, the public&#x02019;s preferences and the WTP for the COVID-19 vaccine were calculated using the DCE method in Iran.</p><p id="Par33">Respondents prefer individuals with an underlying illness, employed in the healthcare sector, a high potential for virus spread in the community, the necessary job for the community, and an increased cost of death for the community to get the vaccine. The findings showed that although the rate of virus spread had the highest impact on preferences, employment in the healthcare sector and the high cost of death for the community were also preferred. These findings were consistent with the results of Luyten et al.&#x02019;s [<xref ref-type="bibr" rid="CR12">12</xref>] study, showing that the coefficients of underlying disease characteristics, the necessary job for the community, the rate of virus spread, and death costs for the community were high and preferred in individuals&#x02019; choices.</p><p id="Par34">While the elderly are referred to as the most at-risk groups for COVID-19, the age coefficient was not statistically significant in this study, indicating that in the respondents&#x02019; viewpoints, age was not the criterion for deciding whether to get a vaccine. A study by Luyten et al. [<xref ref-type="bibr" rid="CR12">12</xref>] showed that age was statistically significant; but, similar to our findings, age had the lowest coefficient among other attributes. The reason that age was not significant was probably people&#x02019;s low awareness of the odds of death with increasing age, which requires planning to promote public awareness in this regard. It is also possible that the public&#x02019;s preference was in favor of the youth.</p><p id="Par35">The COVID-19 vaccination policy in Iran according to the national vaccination guideline is carried out in four priority phases. The first phase includes health personnel who deal directly with patients with COVID-19 and the elderly with severe underlying diseases and chemical, respiratory, and upper 50% veterans, the second phase includes high-risk groups such as the elderly aged over 65 years and individuals aged 16&#x02013;64 years, who have an underlying disease, the third phase includes people in crowded centers who have a lower risk of infection than the population of the previous stages, individuals aged 55&#x02013;64 years without an underlying disease, and people in essential occupations and services, including those healthcare workers who are not in the front line, and the fourth phase involves the general public [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par36">The public&#x02019;s preference for choosing the COVID-19 vaccine increases with higher efficacy and a longer duration of protection and decreases with the high price and severe complications. The location of vaccine production also affects the preferences, and the imported vaccine has a higher chance of acceptance than domestically produced vaccines. These findings were consistent with Dong et al.&#x02019;s [<xref ref-type="bibr" rid="CR17">17</xref>] study in China.</p><p id="Par37">A DCE study for elicit preferences of the Quebec population toward a COVID-19 vaccination program found effectiveness, side effects, the duration of the protective effect, and the origin of the vaccine were the most preferred attributes [<xref ref-type="bibr" rid="CR26">26</xref>]. This study supports our findings.</p><p id="Par38">The results of the study showed that according to the respondents, the imported vaccines had a higher chance of acceptance than the domestically produced vaccines, showing that people have less trust in the domestically produced vaccines or have less desire for domestically produced vaccines, which requires planning to build trust in people toward domestically produced vaccines. It is worth noting that the <italic>P</italic>-value of this attribute was close to 0.05, which is also likely to be insignificant.</p><p id="Par39">The results showed that the highest coefficient was related to the efficacy attribute, showing that, in people&#x02019;s viewpoint, vaccine efficacy was the most important attribute in choosing the vaccine. This finding was consistent with the results of Dong et al.&#x02019;s [<xref ref-type="bibr" rid="CR17">17</xref>] study. Additionally, efficacy was found to be the factor that most influenced vaccine selection in a DCE survey in the UK; further, the positive effect of high efficacy was more pronounced for those aged &#x02265;&#x000a0;55 years [<xref ref-type="bibr" rid="CR27">27</xref>]. An Internet-based DCE survey administered in Chinese provinces found that the public preferred the high effectiveness of the vaccine [<xref ref-type="bibr" rid="CR28">28</xref>]. These studies support our findings that vaccine efficacy was the most important attribute in choosing the vaccine.</p><p id="Par40">Estimating the willingness for final payment shows that respondents are willing to pay more for a vaccine with higher efficacy and a longer duration of protection than other attributes. As the vaccine complications increase, individuals&#x02019; WTP will decrease. This finding was in line with Dong et al.&#x02019;s [<xref ref-type="bibr" rid="CR17">17</xref>] study.</p><p id="Par41">Being aware of the public&#x02019;s preferences for vaccination, including concerns about severe complications and the WTP for vaccination, may help policymakers decide on the COVID-19 vaccine and the successful implementation of the COVID-19 vaccination in national programs requires enough attention to the public&#x02019;s preferences. The exchange between health, economy, and the health system is complicated, and the exact value of public opinion compared to the opinions of experts and politicians is unclear. Nevertheless, given the collective dimensions of the COVID-19 pandemic, public opinion preferences are a fundamental input value for discussion.</p><p id="Par42">Several limitations exist in the present study. First, an online survey may create a selection bias. Individuals who did not have access to the Internet or had poor literacy were thus excluded. However, 84% of residents have access to the Internet in Iran [<xref ref-type="bibr" rid="CR29">29</xref>], which may have limited this bias. Second, because of the COVID-19 epidemic conditions and social distance, we used the convenience sampling method may not be representative of the country&#x02019;s population. Additionally, most of the people who participated in our study were educated; thus, any generalization of these results should be undertaken with caution. Third, as a tool to measure the preferences, the DCE cannot include too many attributes and levels, which makes it different from the real situation. There is still debate about the optimal number of attributes in the literature. However, the more attributes there are, the more difficult it will be to compare options or sets of choices. Based on studies, between four and six attributes are acceptable and no more than eight attributes should be specified [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec13"><title>Conclusions</title><p id="Par43">Generally, the WTP for the COVID-19 vaccine in Iran was higher than the cost of the vaccine (the cost of the vaccine in Iran was from US$4 to US$14.5 per dose [<xref ref-type="bibr" rid="CR32">32</xref>]); however, the WTP varied depending on the vaccine attributes. Furthermore, we found that attribute employment in the health sector, potential capacity to spread the virus, the necessary job for society, underlying disease, and the cost to the community were important for prioritizing vaccination that was in line with government policy and practice.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec14"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41669_2022_359_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 225 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn id="Fn1"><label>1</label><p id="Par18"><italic>n</italic> = 3<sup>3</sup>*2*5.</p></fn><fn id="Fn2"><label>2</label><p id="Par19">269*270/2.</p></fn><fn id="Fn3"><label>3</label><p id="Par20"><italic>n</italic> = 3<sup>2</sup>*2<sup>4</sup>.</p></fn><fn id="Fn4"><label>4</label><p id="Par21">143*144/2.</p></fn></fn-group><notes><title>Declarations</title><notes notes-type="funding"><title>Funding</title><p>This work is based upon research funded by the Iran National Science Foundation under project No. 4000775.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of interest/Competing interests</title><p id="Par44">Alireza Darrudi, Rajabali Daroudi, Masud Yunesian, and Ali Akbari Sari have conflicts of interest that are directly relevant to the content of this article.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par45">The Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.SPH.REC.1400.006) approved this study. Ethical considerations were taken into account during data collection and analysis. The confidentiality of the participants was protected, and no personal information could be identified in any publications arising from the study. Participants were informed that their participation is entirely voluntary.</p></notes><notes id="FPar3"><title>Consent to Participate</title><p id="Par46">Informed consent was obtained from all the respondents included in the study.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par47">Not applicable.</p></notes><notes id="FPar5"><title>Availability of data and material</title><p id="Par48">The data used in the study are available from the corresponding author on reasonable request.</p></notes><notes id="FPar6"><title>Code availability</title><p id="Par49">We used STATA SE software version 13.1 codes for our analyses. The codes are available on the STATA Corp website.</p></notes><notes><title>Authors&#x02019; contributions</title><p>AD participated in designing the study, gathering data, analyzing and interpreting data, and writing the manuscript. RD participated in designing the study, analyzing and interpreting the data, and writing the manuscript. AAS participated in designing the study, interpreting the data, and writing the manuscript. MY provided advice on the study&#x02019;s implementation and the data collection. All authors read and approved the final version of the article.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Liang</surname><given-names>CK</given-names></name><name><surname>Assantachai</surname><given-names>P</given-names></name><name><surname>Auyeung</surname><given-names>TW</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>COVID-19 and older people in Asia: Asian Working Group for Sarcopenia calls to action</article-title><source>Geriatr Gerontol Int</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1111/ggi.13939</pub-id><pub-id pub-id-type="pmid">32365259</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Worldometer. COVID-19 data. 2021. <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1">https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1</ext-link>. Accessed 20 Nov 2021.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Worldometer. COVID-19 data. 2021. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/country/iran/https://www.worldometers.info/coronavirus/country/iran/">https://www.worldometers.info/coronavirus/country/iran/https://www.worldometers.info/coronavirus/country/iran/</ext-link>. Accessed 20 Nov 2021.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><etal/></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>19</issue><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W-j</given-names></name><name><surname>Ni</surname><given-names>Z-y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>W-h</given-names></name><name><surname>Ou</surname><given-names>C-q</given-names></name><name><surname>He</surname><given-names>J-X</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>18</issue><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harapan</surname><given-names>H</given-names></name><name><surname>Anwar</surname><given-names>S</given-names></name><name><surname>Bustamam</surname><given-names>A</given-names></name><name><surname>Radiansyah</surname><given-names>A</given-names></name><name><surname>Angraini</surname><given-names>P</given-names></name><name><surname>Fasli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Willingness to pay for a dengue vaccine and its associated determinants in Indonesia: a community-based, cross-sectional survey in Aceh</article-title><source>Acta Trop</source><year>2017</year><volume>166</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.11.035</pub-id><pub-id pub-id-type="pmid">27908746</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palanca-Tan</surname><given-names>R</given-names></name></person-group><article-title>The demand for a dengue vaccine: a contingent valuation survey in Metro Manila</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>7</issue><fpage>914</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.12.011</pub-id><pub-id pub-id-type="pmid">18206277</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harapan</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>AL</given-names></name><name><surname>Yufika</surname><given-names>A</given-names></name><name><surname>Winardi</surname><given-names>W</given-names></name><name><surname>Anwar</surname><given-names>S</given-names></name><name><surname>Gan</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia</article-title><source>Hum Vaccin Immunother</source><year>2020</year><volume>16</volume><issue>12</issue><fpage>3074</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1819741</pub-id><pub-id pub-id-type="pmid">32991230</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everett</surname><given-names>JA</given-names></name></person-group><article-title>The 12iItem Social and Economic Conservatism Scale (SECS)</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e82131</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082131</pub-id><pub-id pub-id-type="pmid">24349200</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeli</surname><given-names>OA</given-names></name><name><surname>Rahimi kah kashi</surname><given-names>S</given-names></name></person-group><article-title>Estimating willingness to pay for the Covid-19 vaccine using the conditional valuation method</article-title><source>Health Monit J Iran Instit Health Sci Res.</source><year>2021</year><volume>20</volume><issue>2</issue><fpage>223</fpage><lpage>236</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meshkani</surname><given-names>Z</given-names></name><name><surname>Zarei</surname><given-names>L</given-names></name><name><surname>Hajimoladarvish</surname><given-names>N</given-names></name><name><surname>Arabloo</surname><given-names>J</given-names></name><name><surname>Rezapour</surname><given-names>A</given-names></name><name><surname>Farabi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Private demand for Covid-19 vaccine: a contingent assessment from a low-and middle-income country</article-title><source>Iran J Pharm Res.</source><year>2021</year><volume>20</volume><issue>3</issue><fpage>223</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">34903984</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luyten</surname><given-names>J</given-names></name><name><surname>Tubeuf</surname><given-names>S</given-names></name><name><surname>Kessels</surname><given-names>R</given-names></name></person-group><article-title>Who should get it first? Public preferences for distributing a COVID-19 vaccine</article-title><source>Covid Econ Vetted Real-Time Papers.</source><year>2020</year><volume>57</volume><fpage>1</fpage><lpage>19</lpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>LL</given-names></name></person-group><article-title>Making hard choices: rationing health care services</article-title><source>J Legal Med</source><year>2011</year><volume>32</volume><issue>1</issue><fpage>27</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1080/01947648.2011.550825</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappelen</surname><given-names>AW</given-names></name><name><surname>Norheim</surname><given-names>OF</given-names></name></person-group><article-title>Responsibility, fairness and rationing in health care</article-title><source>Health Policy</source><year>2006</year><volume>76</volume><issue>3</issue><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.healthpol.2005.06.013</pub-id><pub-id pub-id-type="pmid">16112248</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmani</surname><given-names>K</given-names></name><name><surname>Rezayatmand</surname><given-names>R</given-names></name><name><surname>Sadeghpour</surname><given-names>N</given-names></name><name><surname>Nikaeen</surname><given-names>M</given-names></name><name><surname>Arabi</surname><given-names>S</given-names></name><name><surname>Molavi</surname><given-names>TY</given-names></name></person-group><article-title>Policy-making for rationing in the healthcare system: a review to provide suggestions for Iran</article-title><source>Manag Strategies Health Syst.</source><year>2018</year><volume>3</volume><issue>3</issue><fpage>249</fpage><lpage>262</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Ronaldson</surname><given-names>S</given-names></name></person-group><article-title>Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods</article-title><source>Br Med Bull</source><year>2012</year><volume>103</volume><issue>1</issue><fpage>21</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/bmb/lds020</pub-id><pub-id pub-id-type="pmid">22859714</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>RH</given-names></name><name><surname>Wong</surname><given-names>ELY</given-names></name><name><surname>Hung</surname><given-names>CT</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Public preference for COVID-19 vaccines in China: a discrete choice experiment</article-title><source>Health Expect</source><year>2020</year><volume>23</volume><issue>6</issue><fpage>1543</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1111/hex.13140</pub-id><pub-id pub-id-type="pmid">33022806</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreps</surname><given-names>S</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Brownstein</surname><given-names>JS</given-names></name><name><surname>Hswen</surname><given-names>Y</given-names></name><name><surname>Garibaldi</surname><given-names>BT</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Factors associated with US adults&#x02019; likelihood of accepting COVID-19 vaccination</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>10</issue><fpage>e2025594-e</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.25594</pub-id><pub-id pub-id-type="pmid">33079199</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>A</given-names></name><name><surname>Maitland</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Nicholas</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Individual preferences for COVID-19 vaccination in China</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>2</issue><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.12.009</pub-id><pub-id pub-id-type="pmid">33328140</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borriello</surname><given-names>A</given-names></name><name><surname>Master</surname><given-names>D</given-names></name><name><surname>Pellegrini</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>JM</given-names></name></person-group><article-title>Preferences for a COVID-19 vaccine in Australia</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>3</issue><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.12.032</pub-id><pub-id pub-id-type="pmid">33358265</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>G</given-names></name><name><surname>van Driel</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>L</given-names></name></person-group><article-title>Systematic review and validity assessment of methods used in discrete choice experiments of primary healthcare professionals</article-title><source>Health Econ Rev.</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s13561-020-00295-8</pub-id><pub-id pub-id-type="pmid">31916025</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrampour</surname><given-names>M</given-names></name><name><surname>Byrnes</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>R</given-names></name><name><surname>Scuffham</surname><given-names>PA</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name></person-group><article-title>Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods</article-title><source>Eur J Health Econ</source><year>2020</year><volume>21</volume><issue>7</issue><fpage>983</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1007/s10198-020-01189-6</pub-id><pub-id pub-id-type="pmid">32367379</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaels-Igbokwe</surname><given-names>C</given-names></name><name><surname>MacDonald</surname><given-names>S</given-names></name><name><surname>Currie</surname><given-names>GR</given-names></name></person-group><article-title>Individual preferences for child and adolescent vaccine attributes: a systematic review of the stated preference literature</article-title><source>Patient</source><year>2017</year><volume>10</volume><issue>6</issue><fpage>687</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1007/s40271-017-0244-x</pub-id><pub-id pub-id-type="pmid">28474295</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zartab</surname><given-names>S</given-names></name><name><surname>Nikfar</surname><given-names>S</given-names></name><name><surname>Karimpour-Fard</surname><given-names>N</given-names></name><name><surname>Jamshidi</surname><given-names>A</given-names></name><name><surname>Varahrami</surname><given-names>V</given-names></name><name><surname>Homayouni</surname><given-names>A</given-names></name><etal/></person-group><article-title>A systematic review of discrete choice experiment studies in rheumatoid arthritis biological medicines</article-title><source>Mediterr J Rheumatol.</source><year>2021</year><volume>32</volume><issue>2</issue><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.31138/mjr.32.2.104</pub-id><pub-id pub-id-type="pmid">34447905</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Islamic Parliament Research Center (IPRC). Investigation of COVID-19 vaccine distribution program in Iran and other countries. 2021. <ext-link ext-link-type="uri" xlink:href="https://rc.majlis.ir/fa/report/show/1677575">https://rc.majlis.ir/fa/report/show/1677575</ext-link>. Accessed 28 Jun 2022.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morillon</surname><given-names>GF</given-names></name><name><surname>Poder</surname><given-names>TG</given-names></name></person-group><article-title>Public preferences for a COVID-19 vaccination program in Quebec: a discrete choice experiment</article-title><source>Pharmacoeconomics</source><year>2022</year><volume>40</volume><issue>3</issue><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/s40273-021-01124-4</pub-id><pub-id pub-id-type="pmid">35048317</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPhedran</surname><given-names>R</given-names></name><name><surname>Toombs</surname><given-names>B</given-names></name></person-group><article-title>Efficacy or delivery? An online discrete choice experiment to explore preferences for COVID-19 vaccines in the UK</article-title><source>Econ Lett</source><year>2021</year><volume>200</volume><fpage>109747</fpage><pub-id pub-id-type="doi">10.1016/j.econlet.2021.109747</pub-id><pub-id pub-id-type="pmid">33551522</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Fu C, Zhu F, Pei S, Li S, Zhang L, Sun X, et al. Acceptance of and preference for COVID-19 vaccination in healthcare workers: a comparative analysis and discrete choice experiment. medRxiv. 2022:2020.04.09.20060103.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">World Bank. Individuals using the Internet (% of population): Iran, Islamic Rep. 2020. <ext-link ext-link-type="uri" xlink:href="https://data.worldbank.org/indicator/IT.NET.USER.ZS?locations=IR">https://data.worldbank.org/indicator/IT.NET.USER.ZS?locations=IR</ext-link>. Accessed 10 May 2022.</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancsar</surname><given-names>E</given-names></name><name><surname>Louviere</surname><given-names>J</given-names></name></person-group><article-title>Conducting discrete choice experiments to inform healthcare decision making</article-title><source>Pharmacoeconomics</source><year>2008</year><volume>26</volume><issue>8</issue><fpage>661</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.2165/00019053-200826080-00004</pub-id><pub-id pub-id-type="pmid">18620460</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridges</surname><given-names>JF</given-names></name><name><surname>Hauber</surname><given-names>AB</given-names></name><name><surname>Marshall</surname><given-names>D</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Prosser</surname><given-names>LA</given-names></name><name><surname>Regier</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Conjoint analysis applications in health: a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force</article-title><source>Value Health.</source><year>2011</year><volume>14</volume><issue>4</issue><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2010.11.013</pub-id><pub-id pub-id-type="pmid">21669364</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Islamic Republic News Agency. 2021. <ext-link ext-link-type="uri" xlink:href="https://irna.ir/xjFYGp">https://irna.ir/xjFYGp</ext-link>. Accessed 28 Jun 2022.</mixed-citation></ref></ref-list></back></article>
